Manus Neurodynamica, who develop and market products and technologies for neuromotor assessment, will be joining the ABHI UK Pavilion at MEDICA 2021 to launch its non-invasive technology that supports an earlier and more accurate diagnosis of dementias and cognitive impairment.
The NeuroMotor Pen (NMP) is a patented and CE-marked system which combines multiple sensors built into a digital pen with software for administering standardised tasks and a cloud-based analytical engine with a decision support system. The device enables users to record non-invasively and analyse parameters of minute limb and hand motion, enabling quantification of fine motor skill. These parameters are used as ‘digital biomarkers’ to provide objective information to clinicians about movement abnormalities, thus supporting diagnosis and monitoring of Parkinson's Disease and other neuromotor impairments.
As a monitoring (symptoms tracking) tool, the NeuroMotor Pen provides objective measurements with automated record keeping. It provides a non-invasive aid to diagnosis, providing a low-cost alternative to brain scans. The accuracy provides advantages – particularly for measuring response to dopaminergic medication. There are currently no other devices on the market that can measure fine motor skill with the same level of accuracy.
As a diagnostic for Parkinson's Disease, the disruptive technology can aid in timely diagnostic decision making, leading to improved efficiencies in the pathway with potentially better long term clinical outcomes and reduced costs.
Rutger Zietsma, CEO said: “We are delighted to be joining the ABHI UK Pavilion at MEDICA, where we will be launching our innovative technology designed to radically improve patient diagnosis of Parkinson’s and other neuromotor impairments. Using the NeuroMotor Pen can offer a direct cost reduction for disease diagnosis as a replacement for more expensive methods. The product can assist with a timely, accurate diagnosis, increasing early treatment. Moreover, it can assist with treatment optimisation through symptom tracking, which for many patients can delay deterioration to the stage where interventions and long-term care costs increase. We look forward to meeting new partners and distributors at the event.”
Clinical trials and over 10 years of research have demonstrated that the NeuroMotor Pen detects these early signs with high accuracy of over 80% and high sensitivity. The device is implemented both in primary care to support specialist referral decision making as well as Parkinson’s specialist services to support diagnostic and patient monitoring activities.
Manus Neurodynamica is also trialling future product versions for assessment of extrapyramidal adverse effects of antipsychotic drugs that has the potential to optimise treatment and reduce side effects. In addition, a product is in development that combines cognitive assessment with motor skill assessment with applications in early detection of dementia. Only around 68% of over 65’s estimated to have dementia have been diagnosed. Early identification is recognised as substantially increasing the chance of maintaining functional abilities and deferring the point of escalation, where additional care and support is required at home or in a care facility. New screening technologies are required to correctly identify affected patients.
Paul Benton, managing director, international at the ABHI, added: “Early diagnosis and timely access to specialist care is vital for patients, and Manus’s revolutionary technology is helping to make this a reality for patients with dementia. We are delighted that they have chosen to launch their innovative device on the ABHI Pavilion. We look forward to supporting them at MEDICA.”
MEDICA is taking place from 15 – 18 November 2021 and throughout the show, Manus will be located on the ABHI UK Pavilion - Hall 16 Stand K42.
